Shares of CervoMed Inc. (NASDAQ:CRVO – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the seven analysts that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $21.00.
A number of analysts recently commented on the stock. Wall Street Zen raised shares of CervoMed from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Roth Capital set a $7.00 target price on shares of CervoMed in a research report on Thursday, August 20th. Chardan Capital raised shares of CervoMed to a “strong-buy” rating in a report on Monday, August 3rd. Weiss Ratings downgraded shares of CervoMed from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd. Finally, HC Wainwright reiterated a “buy” rating on shares of CervoMed in a research report on Monday, October 5th.
View Our Latest Stock Report on CRVO
Insider Buying and Selling at CervoMed
In other news, CEO John J. Alam purchased 100,000 shares of the stock in a transaction that occurred on Wednesday, November 18th. The shares were acquired at an average price of $1.53 per share, for a total transaction of $153,000.00. Following the acquisition, the chief executive officer directly owned 1,584,078 shares in the company, valued at approximately $2,423,639.34. The trade was a 6.74% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 35.80% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On CervoMed
Several hedge funds and other institutional investors have recently bought and sold shares of the company. NFSG Corp grew its holdings in CervoMed by 283.3% in the third quarter. NFSG Corp now owns 11,500 shares of the company’s stock valued at $34,000 after purchasing an additional 8,500 shares during the last quarter. Caprock Group LLC purchased a new position in shares of CervoMed in the third quarter valued at $34,000. Citizens Financial Group Inc. RI acquired a new position in shares of CervoMed during the 2nd quarter worth $116,000. Byrne Asset Management LLC raised its stake in shares of CervoMed by 248.6% during the 2nd quarter. Byrne Asset Management LLC now owns 51,250 shares of the company’s stock worth $159,000 after buying an additional 36,550 shares during the last quarter. Finally, BlackRock Inc. acquired a new position in shares of CervoMed during the 2nd quarter worth $167,000. 25.15% of the stock is owned by institutional investors and hedge funds.
CervoMed Stock Performance
CervoMed stock opened at $1.46 on Friday. CervoMed has a one year low of $1.27 and a one year high of $10.00. The business has a fifty day moving average of $2.24 and a two-hundred day moving average of $3.20. The company has a market cap of $22.09 million, a P/E ratio of -0.53 and a beta of -0.62.
CervoMed (NASDAQ:CRVO – Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.09. Sell-side analysts predict that CervoMed will post -2.04 EPS for the current year.
CervoMed Company Profile
CervoMed is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases. Its research focuses on therapies intended to address underlying disease processes rather than only manage symptoms. The company’s lead drug candidate, neflamapimod, is an oral, brain-penetrant small molecule designed to inhibit p38 alpha mitogen-activated protein kinase. CervoMed has studied the candidate for dementia with Lewy bodies, a progressive neurodegenerative disorder. CervoMed was formed in 2023 when EIP Pharma combined with Diffusion Pharmaceuticals, which subsequently adopted the CervoMed name.
See Also
- Five stocks we like better than CervoMed
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for CervoMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CervoMed and related companies with MarketBeat.com's FREE daily email newsletter.
